Outcome of the Board Meeting and submission of Audited Financial Results for the quarter and year ended 31st March 2026

Pat Growth 25pctEbitda Margin ExpansionExceptional ItemResults View source PDF Explain this filing

IOLCP · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+8.1%Reaction day

₹110.10

prior close

₹117.00

announcement price

In-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used+0.6%+7.5% vs market

Pharmaceuticals peers, median of 158sector+0.2%+7.8% vs sector

On the reaction day the stock moved 7.5 pts more than Nifty Microcap 250 and 7.8 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-1.3

10m

-1.4

15m

-0.9

30m

+2.9

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+8.1+0.6+7.5+0.2+7.8

Next day

+10.0+1.7+8.3+0.7+9.3

+7.4+1.8+5.6+0.5+6.9

+13.1+3.4+9.7+1.7+11.4

+24.3+4.1+20.1+1.9+22.4

+19.0+4.1+14.9+1.9+17.1

+14.1+2.3+11.8+1.2+12.9

15d

+16.3+1.8+14.6-0.6+16.9

+18.5+10.8+7.8+3.8+14.8

+41.2+10.3+30.9+7.8+33.3

+49.1+14.9+34.1+8.2+40.8

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 158Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

IOL Chemicals & Pharmaceuticals reported standalone revenue of Rs 2,319 crore for FY26, up 11.5% from Rs 2,079 crore in FY25. Profit after tax grew 36% to Rs 137.72 crore from Rs 101 crore. EPS improved to Rs 4.69 from Rs 3.44. The board fixed the 39th AGM for September 2, 2026. The auditors issued an unmodified (clean) opinion on the financial statements. The company announced expansion plans: new Triacetin manufacturing facility with 6,000 MTPA capacity (Rs 16.88 crore capex) and Pantoprazole capacity increase from 240 to 276 MTPA (Rs 5.87 crore capex), both funded through internal accruals. An exceptional item of Rs 11.21 crore was recorded for past service cost due to new Labour Code amendments.

Likely market impact

Strong bottom-line growth with 36% PAT increase and clean audit opinion signals financial health. New capacity expansions in Triacetin and Pantoprazole could support future revenue growth while existing cash-funded capex maintains balance sheet strength.